Category Oncology

Viewing 1–10 of 40

«
of 4
»

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Direct Oral Anticoagulants in Patients Cancer
Professions: Physician

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OT0419

Published: April 2019

Expires: 3/31/2021

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Lisa Lohr, PharmD, BCPS, BCOP

Categories: Cancer , Drug Therapy , Oncology

Specialties: Hematology, Oncology

Topics: Cancer , Oral Anticoagulants
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Direct Oral Anticoagulants in Patients Cancer ((Non-Physician Credit))
Professions: Other Health Professional

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OTN0419

Published: April 2019

Expires: 3/31/2021

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Lisa Lohr, PharmD, BCPS, BCOP

Categories: Cancer , Drug Therapy , Oncology

Specialties: Hematology, Oncology

Topics: Cancer , Oral Anticoagulants
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation
Professions: Physician

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OT0219

Published: February 2019

Expires: 1/31/2021

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Diagnostic Studies , Gynecological , Oncology

Specialties: Gynecology, Hematology, Oncology, Radiology

Topics: Germline BRCA Mutation , Talazoparib in Advanced Breast Cancer
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation ((Non-Physician Credit))
Professions: Other Health Professional

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OTN0219

Published: February 2019

Expires: 1/31/2021

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Diagnostic Studies , Gynecological , Oncology

Specialties: Gynecology, Hematology, Oncology, Radiology

Topics: Germline BRCA Mutation , Talazoparib in Advanced Breast Cancer
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Leukemia Risks Associated with Childhood Exposure to Radiation
Professions: Physician

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OT0119

Published: January 2019

Expires: 12/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology , Pediatrics

Specialties: Hematology, Radiology

Topics: Children , Leukemia , Radiation Exposure
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Leukemia Risks Associated with Childhood Exposure to Radiation ((Non-Physician Credit))
Professions: Other Health Professional

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OTN0119

Published: January 2019

Expires: 12/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology , Pediatrics

Specialties: Hematology, Radiology

Topics: Children , Leukemia , Radiation Exposure
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC
Professions: Physician

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OT1218

Published: Dec 2018

Expires: 12/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology

Specialties: Oncology

Topics: Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC ((Non-Physician Credit))
Professions: Other Health Professional

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OTN1218

Published: Dec 2018

Expires: 12/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology

Specialties: Oncology

Topics: Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity
Professions: Physician

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OT1118

Published: Nov 2018

Expires: 10/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology

Specialties: Oncology

Topics: A TKI in Activating Anticancer Innate Immunity
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity ((Non-Physician Credit))
Professions: Other Health Professional

Price: $10.00
Credits:
- ACCME 1.0 CME
Planner

Test Code: OTN1118

Published: Nov 2018

Expires: 10/31/2020

Sources: Oncology Times
Details

Passing Score: 7/10 (70%)

Authors: Richard Simoneaux

Categories: Oncology

Specialties: Oncology

Topics: A TKI in Activating Anticancer Innate Immunity

Viewing 1–10 of 40

«
of 4
»

Lippincott CMEConnection

Category Oncology

Show

Sort

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Direct Oral Anticoagulants in Patients Cancer

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Direct Oral Anticoagulants in Patients Cancer ((Non-Physician Credit))

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation ((Non-Physician Credit))

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Leukemia Risks Associated with Childhood Exposure to Radiation

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Leukemia Risks Associated with Childhood Exposure to Radiation ((Non-Physician Credit))

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC ((Non-Physician Credit))

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity

Credits:

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity ((Non-Physician Credit))

Credits: